GILEAD SCIENCES, INC. (GILD)
Every FINRA and SEC series the site collects for GILEAD SCIENCES, INC.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
23.2M
Short interest
settlement 2026-08-14
3.2
Days to cover
-4.9% vs prior
40.8%
Short share of volume
2026-09-11
701
Fails to deliver
settlement 2026-08-11
-$11.9M
Insider flow, 90 days
0 buys, 18 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in GILD is 23,183,970 shares, down 2,077,941 shares over the last month. Over the last 48 readings it ranged from 15,804,496 shares (15 October 2025) to 25,725,417 shares (29 May 2026). At the reported average volume of 7.1M shares a day that is 3.2 days to cover.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/gild" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 23,183,970 | -4.9% | 7,146,553 | 3.24 |
| 2026-07-31 | 24,385,621 | -3.5% | 6,312,993 | 3.86 |
| 2026-07-15 | 25,261,911 | -0.9% | 6,888,646 | 3.67 |
| 2026-06-30 | 25,484,358 | +6.8% | 9,596,162 | 2.66 |
| 2026-06-15 | 23,861,932 | -7.2% | 8,868,841 | 2.69 |
| 2026-05-29 | 25,725,417 | +11.2% | 6,740,926 | 3.82 |
| 2026-05-15 | 23,135,379 | +0.4% | 6,501,415 | 3.56 |
| 2026-04-30 | 23,051,059 | +1.3% | 5,681,363 | 4.06 |
| 2026-04-15 | 22,751,109 | +5.7% | 4,803,620 | 4.74 |
| 2026-03-31 | 21,524,970 | +7.7% | 6,659,884 | 3.23 |
| 2026-03-13 | 19,985,404 | +8.3% | 5,945,110 | 3.36 |
| 2026-02-27 | 18,454,950 | -15.7% | 6,745,011 | 2.74 |
| 2026-02-13 | 21,892,924 | -7.6% | 8,417,817 | 2.60 |
| 2026-01-30 | 23,684,789 | +3.1% | 9,218,456 | 2.57 |
| 2026-01-15 | 22,974,646 | -0.8% | 6,098,981 | 3.77 |
| 2025-12-31 | 23,154,890 | +7.0% | 6,326,979 | 3.66 |
| 2025-12-15 | 21,650,110 | +17.1% | 6,783,914 | 3.19 |
| 2025-11-28 | 18,479,939 | +8.7% | 7,394,434 | 2.50 |
| 2025-11-14 | 17,007,031 | -5.4% | 7,329,337 | 2.32 |
| 2025-10-31 | 17,975,927 | +13.7% | 7,065,409 | 2.54 |
| 2025-10-15 | 15,804,496 | -12.4% | 7,648,238 | 2.07 |
| 2025-09-30 | 18,035,549 | -1.2% | 7,429,719 | 2.43 |
| 2025-09-15 | 18,249,455 | +3.9% | 6,855,608 | 2.66 |
| 2025-08-29 | 17,562,109 | -3.6% | 5,089,106 | 3.45 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of GILD volume is 40.8%, up 0.4 points over the last five sessions. Over the last 52 readings it ranged from 13.0% (10 August 2026) to 57.3% (4 September 2026). The latest reading is 6.8 points above the 30-session average of 34.0%, on 1.2M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 504K | 1.2M | 40.8% | 4,715 |
| 2026-09-10 | 618K | 1.6M | 39.6% | 1,699 |
| 2026-09-09 | 437K | 1.4M | 32.0% | 442 |
| 2026-09-08 | 552K | 1.5M | 37.2% | 291 |
| 2026-09-04 | 858K | 1.5M | 57.3% | 4,907 |
| 2026-09-03 | 611K | 1.5M | 40.4% | 4,328 |
| 2026-09-02 | 637K | 1.8M | 34.5% | 4,964 |
| 2026-09-01 | 581K | 1.7M | 33.9% | 3,411 |
| 2026-08-31 | 517K | 1.7M | 30.3% | 5,735 |
| 2026-08-28 | 418K | 1.4M | 30.8% | 9,994 |
| 2026-08-27 | 606K | 1.3M | 47.0% | 767 |
| 2026-08-26 | 632K | 1.5M | 41.9% | 7,815 |
| 2026-08-25 | 717K | 1.7M | 41.7% | 11,971 |
| 2026-08-24 | 633K | 1.5M | 43.2% | 217 |
| 2026-08-21 | 506K | 1.5M | 33.5% | 12,710 |
| 2026-08-20 | 611K | 2.0M | 31.0% | 413 |
| 2026-08-19 | 867K | 2.3M | 38.1% | 17,525 |
| 2026-08-18 | 859K | 1.9M | 45.4% | 46,407 |
| 2026-08-17 | 553K | 1.3M | 41.9% | 17,476 |
| 2026-08-14 | 546K | 1.2M | 43.9% | 3,022 |
| 2026-08-13 | 529K | 1.7M | 30.6% | 0 |
| 2026-08-12 | 556K | 2.0M | 27.7% | 3,908 |
| 2026-08-11 | 482K | 2.0M | 24.7% | 4,035 |
| 2026-08-10 | 331K | 2.5M | 13.0% | 78 |
| 2026-08-07 | 322K | 2.4M | 13.2% | 521 |
| 2026-08-06 | 509K | 3.2M | 16.1% | 291 |
| 2026-08-05 | 857K | 4.0M | 21.5% | 1,976 |
| 2026-08-04 | 946K | 3.2M | 29.2% | 3,058 |
| 2026-08-03 | 842K | 2.7M | 31.0% | 1,949 |
| 2026-07-31 | 600K | 2.2M | 27.8% | 662 |
Fails to deliver
SEC, by settlement date. JSONAs of 11 August 2026, the fails-to-deliver balance in GILD is 701 shares, up 423 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (19 March 2026) to 130,529 shares (23 February 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-11 | 701 | $133.06 | $93K |
| 2026-08-10 | 278 | $133.21 | $37K |
| 2026-08-06 | 40 | $131.76 | $5K |
| 2026-08-04 | 27 | $131.15 | $4K |
| 2026-08-03 | 29,318 | $130.21 | $3.8M |
| 2026-07-30 | 199 | $132.73 | $26K |
| 2026-07-22 | 179 | $130.28 | $23K |
| 2026-07-20 | 121 | $134.28 | $16K |
| 2026-07-15 | 24 | $130.04 | $3K |
| 2026-07-14 | 473 | $131.40 | $62K |
| 2026-07-09 | 6,972 | $135.82 | $947K |
| 2026-07-06 | 1,029 | $131.27 | $135K |
| 2026-07-02 | 351 | $125.97 | $44K |
| 2026-06-22 | 39 | $123.76 | $5K |
| 2026-06-12 | 2 | $125.87 | $252 |
| 2026-06-10 | 4 | $125.50 | $502 |
| 2026-06-08 | 4 | $129.16 | $517 |
| 2026-06-03 | 7,392 | $127.57 | $943K |
| 2026-04-29 | 2 | $129.26 | $259 |
| 2026-04-24 | 3,148 | $133.64 | $421K |
| 2026-04-20 | 400 | $137.64 | $55K |
| 2026-04-17 | 4 | $138.55 | $554 |
| 2026-04-15 | 11 | $140.45 | $2K |
| 2026-04-14 | 690 | $139.03 | $96K |
| 2026-04-10 | 644 | $142.09 | $92K |
| 2026-04-08 | 5 | $138.80 | $694 |
| 2026-04-07 | 41 | $140.13 | $6K |
| 2026-04-06 | 9,676 | $139.71 | $1.4M |
| 2026-04-02 | 43 | $140.30 | $6K |
| 2026-03-30 | 1 | $134.25 | $134 |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at GILD reported 18 open-market sells worth $11.9M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: O'Day Daniel Patrick (Chairman & CEO) on 2026-09-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | O'Day Daniel Patrick | Chairman & CEO | Sell | 5K | $149.38 | $808K | 577K |
| 2026-09-01 | O'Day Daniel Patrick | Chairman & CEO | Sell | 8K | $148.36 | $1.2M | 583K |
| 2026-09-01 | O'Day Daniel Patrick | Chairman & CEO | Sell | 2K | $147.51 | $236K | 591K |
| 2026-08-26 | WELTERS ANTHONY | n/a | Sell | 7K | $148.82 | $1.0M | 13K |
| 2026-08-26 | WELTERS ANTHONY | n/a | Sell | 3K | $148.24 | $504K | 20K |
| 2026-08-26 | WELTERS ANTHONY | n/a | Option exercise | 10K | $61.35 | $631K | 23K |
| 2026-08-26 | WELTERS ANTHONY | n/a | Sell | 5K | $148.82 | $685K | 13K |
| 2026-08-26 | WELTERS ANTHONY | n/a | Sell | 3K | $148.31 | $462K | 17K |
| 2026-08-26 | WELTERS ANTHONY | n/a | Option exercise | 8K | $60.67 | $468K | 21K |
| 2026-08-20 | Bluestone Jeffrey | n/a | Sell | 335 | $146.26 | $49K | 10K |
| 2026-08-20 | Bluestone Jeffrey | n/a | Option exercise | 335 | $61.35 | $21K | 10K |
| 2026-08-20 | Bluestone Jeffrey | n/a | Sell | 26 | $146.36 | $4K | 10K |
| 2026-08-20 | Bluestone Jeffrey | n/a | Option exercise | 26 | $67.45 | $2K | 10K |
| 2026-08-20 | Bluestone Jeffrey | n/a | Sell | 2K | $145.73 | $242K | 10K |
| 2026-08-20 | Bluestone Jeffrey | n/a | Option exercise | 2K | $67.45 | $112K | 12K |
| 2026-08-20 | Bluestone Jeffrey | n/a | Sell | 2K | $144.92 | $263K | 10K |
| 2026-08-20 | Bluestone Jeffrey | n/a | Option exercise | 2K | $67.45 | $122K | 12K |
| 2026-08-20 | Bluestone Jeffrey | n/a | Sell | 1K | $143.75 | $167K | 10K |
| 2026-08-20 | Bluestone Jeffrey | n/a | Option exercise | 1K | $67.45 | $79K | 11K |
| 2026-08-17 | Mercier Johanna | Chief Comm & Corp Aff Officer | Sell | 11K | $138.04 | $1.6M | 118K |
| 2026-08-17 | Mercier Johanna | Chief Comm & Corp Aff Officer | Sell | 17K | $137.37 | $2.3M | 130K |
| 2026-08-17 | Mercier Johanna | Chief Comm & Corp Aff Officer | Option exercise | 2K | $72.34 | $137K | 146K |
| 2026-08-17 | Mercier Johanna | Chief Comm & Corp Aff Officer | Option exercise | 23K | $66.64 | $1.5M | 144K |
| 2026-08-17 | Dickinson Andrew D | Chief Financial Officer | Sell | 3K | $138.36 | $415K | 166K |
| 2026-08-03 | O'Day Daniel Patrick | Chairman & CEO | Sell | 600 | $131.34 | $79K | 592K |
| 2026-08-03 | O'Day Daniel Patrick | Chairman & CEO | Sell | 8K | $130.80 | $1.0M | 593K |
| 2026-08-03 | O'Day Daniel Patrick | Chairman & CEO | Sell | 7K | $129.66 | $869K | 600K |
| 2026-06-01 | O'Day Daniel Patrick | Chairman & CEO | Sell | 1K | $132.97 | $138K | 618K |
| 2026-06-01 | O'Day Daniel Patrick | Chairman & CEO | Sell | 3K | $132.22 | $405K | 619K |
| 2026-06-01 | O'Day Daniel Patrick | Chairman & CEO | Sell | 11K | $131.10 | $1.4M | 622K |
| 2026-05-15 | Mercier Johanna | Chief Comm & Corp Aff Officer | Sell | 700 | $132.75 | $93K | 126K |
| 2026-05-15 | Mercier Johanna | Chief Comm & Corp Aff Officer | Sell | 8K | $132.23 | $1.1M | 126K |
| 2026-05-15 | Mercier Johanna | Chief Comm & Corp Aff Officer | Sell | 11K | $131.19 | $1.5M | 135K |
| 2026-05-15 | Mercier Johanna | Chief Comm & Corp Aff Officer | Sell | 8K | $130.29 | $1.0M | 146K |
| 2026-05-15 | Mercier Johanna | Chief Comm & Corp Aff Officer | Option exercise | 25K | $66.64 | $1.7M | 154K |
| 2026-05-15 | Dickinson Andrew D | Chief Financial Officer | Sell | 3K | $132.27 | $397K | 173K |
| 2026-04-30 | Horning Sandra | n/a | Grant | 1K | $0.00 | $0 | 6K |
| 2026-04-30 | MANWANI HARISH | n/a | Tax withholding | 224 | $130.84 | $29K | 15K |
| 2026-04-30 | MANWANI HARISH | n/a | Grant | 1K | $0.00 | $0 | 15K |
| 2026-04-30 | Rodriguez Javier | n/a | Grant | 1K | $0.00 | $0 | 13K |
| 2026-04-30 | WELTERS ANTHONY | n/a | Grant | 1K | $0.00 | $0 | 13K |
| 2026-04-30 | LOVE TED W | n/a | Grant | 1K | $0.00 | $0 | 5K |
| 2026-04-30 | Bluestone Jeffrey | n/a | Grant | 1K | $0.00 | $0 | 10K |
| 2026-04-30 | BARTON JACQUELINE K | n/a | Grant | 1K | $0.00 | $0 | 27K |
| 2026-04-28 | O'Day Daniel Patrick | Chairman & CEO | Sell | 3K | $130.01 | $397K | 633K |
| 2026-04-28 | O'Day Daniel Patrick | Chairman & CEO | Sell | 7K | $128.79 | $895K | 636K |
| 2026-04-15 | Mercier Johanna | Chief Comm & Corp Aff Officer | Sell | 3K | $140.96 | $423K | 129K |
| 2026-04-15 | Dickinson Andrew D | Chief Financial Officer | Sell | 3K | $140.96 | $423K | 176K |
| 2026-03-27 | O'Day Daniel Patrick | Chairman & CEO | Sell | 10K | $136.82 | $1.4M | 643K |
| 2026-03-16 | Mercier Johanna | Chief Comm & Corp Aff Officer | Sell | 3K | $144.23 | $433K | 132K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON7 Form 144 notices on file for GILD worth $15.6M at the prices reported; 7 in the last 90 days worth $15.6M. Latest: ANTHONY WELTERS filed on 2026-08-26 to sell 18,000 shares ($2.7M) from 2026-08-26.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-26 | ANTHONY WELTERSDirector | 18K | $2.7M | 0.001% | 2026-08-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-20 | JEFFREY BLUESTONEDirector | 5K | $738K | 0.000% | 2026-08-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-17 | JOHANNA MERCIEROfficer | 28K | $3.9M | 0.002% | 2026-08-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-17 | ANDREW DICKINSONOfficer | 3K | $415K | 0.000% | 2026-08-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-03 | DANIEL O'DAYDirector, Officer | 55K | $7.2M | 0.004% | 2026-08-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-15 | JOHANNA MERCIEROfficer | 3K | $390K | 0.000% | 2026-07-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-15 | ANDREW DICKINSONOfficer | 3K | $390K | 0.000% | 2026-07-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
13F holders
Tracked managers holding GILD at their latest 13F. JSON9 of the 30 tracked managers held GILD at their latest 13F, $1.94B in total at quarter-end prices. Citadel Advisors is the largest at $704.5M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 5.6M | $704.5M | 0.08% | -488K |
| D. E. Shaw & Co. | 2026-06-30 | 2.5M | $314.0M | 0.15% | +2.3M |
| Renaissance Technologies | 2026-06-30 | 2.2M | $280.1M | 0.39% | +65K |
| Millennium Management | 2026-06-30 | 2.2M | $275.4M | 0.10% | new or n/a |
| Point72 Asset Management | 2026-06-30 | 1.5M | $186.9M | 0.21% | +1.4M |
| AQR Capital Management | 2026-06-30 | 695K | $86.9M | 0.03% | -469K |
| Two Sigma Investments | 2026-06-30 | 409K | $51.7M | 0.04% | +386K |
| Bridgewater Associates | 2026-06-30 | 291K | $36.7M | 0.15% | +110K |
| Fisher Asset Management | 2026-06-30 | 19K | $2.4M | 0.00% | +8K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 2026 (quarter ended 2026-06-30) GILEAD SCIENCES, INC. reported revenue of $7.80B, up 10.2% from the same quarter a year earlier, and net loss of $10.50B (-8.45 diluted EPS). In FY 2025 it generated $10.02B of operating cash flow and spent $1.92B on buybacks and $4.00B on dividends.
- Debt
- $26.25B
- Equity
- $11.83B
- Total assets
- $49.36B
- Shares outstanding
- 1,239,955,155
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.80B | -$10.50B | -134.5% | -8.45 |
| Q1 2026 | 2026-03-31 | $6.96B | $2.02B | 29.0% | 1.61 |
| Q4 2025derived | 2025-12-31 | $7.92B | $2.18B | 27.5% | n/a |
| Q3 2025 | 2025-09-30 | $7.77B | $3.05B | 39.3% | 2.43 |
| Q2 2025 | 2025-06-30 | $7.08B | $1.96B | 27.7% | 1.56 |
| Q1 2025 | 2025-03-31 | $6.67B | $1.31B | 19.7% | 1.04 |
| Q4 2024derived | 2024-12-31 | $7.57B | $1.78B | 23.6% | n/a |
| Q3 2024 | 2024-09-30 | $7.54B | $1.25B | 16.6% | 1.00 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $29.44B | $8.51B | $10.02B | $563.0M | $1.92B | $4.00B |
| FY 2024 | 2024-12-31 | $28.75B | $480.0M | $10.83B | $523.0M | $1.15B | $3.92B |
| FY 2023 | 2023-12-31 | $27.12B | $5.67B | $8.01B | $585.0M | $1.00B | $3.81B |
| FY 2022 | 2022-12-31 | $27.28B | $4.59B | $9.07B | $728.0M | $1.40B | $3.71B |
| FY 2021 | 2021-12-31 | $27.30B | $6.22B | $11.38B | $579.0M | $546.0M | $3.60B |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
GILEAD SCIENCES, INC. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows GILEAD SCIENCES, INC. (GILD), SEC CIK 882095, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-11.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-08-26.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-09-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 882095Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 09:50 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
- KYMRKymera Therapeutics, Inc.
- ADPTAdaptive Biotechnologies Corp
- TWSTTwist Bioscience Corp
- HALOHALOZYME THERAPEUTICS, INC.
- KRYSKrystal Biotech, Inc.
- NBIXNEUROCRINE BIOSCIENCES INC
- RVMDRevolution Medicines, Inc.
- AMGNAMGEN INC
- MAZEMaze Therapeutics, Inc.
- RXRXRECURSION PHARMACEUTICALS, INC.
- APGEApogee Therapeutics, Inc.
- FENCFENNEC PHARMACEUTICALS INC.
- PCVXVaxcyte, Inc.
- BIIBBIOGEN INC.
- VORVor Biopharma Inc.
- EXELEXELIXIS, INC.
- SRRKScholar Rock Holding Corp
- ADMAADMA BIOLOGICS, INC.
- VCELVericel Corp
- TECHBIO-TECHNE Corp
- ARTVArtiva Biotherapeutics, Inc.
- BCRXBIOCRYST PHARMACEUTICALS INC
- VIRVir Biotechnology, Inc.
- IOVAIOVANCE BIOTHERAPEUTICS, INC.
Datasets
Frequently Asked Questions
How much of GILD is sold short?
What is GILD's daily short volume?
Does GILD have fails to deliver?
Are GILD insiders buying or selling?
Have GILD insiders filed to sell?
What did GILD report last quarter?
Which funds hold GILD?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.